Journal article
Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era
Blood cancer journal (New York), Vol.13(1), pp.81-81
05/17/2023
DOI: 10.1038/s41408-023-00847-1
PMCID: PMC10188323
PMID: 37193683
Abstract
How to identify follicular lymphoma (FL) patients with low disease burden but high risk for early progression is unclear. Building on a prior study demonstrating the early transformation of FLs with high variant allele frequency (VAF) BCL2 mutations at activation-induced cytidine deaminase (AICDA) sites, we examined 11 AICDA mutational targets, including BCL2, BCL6, PAX5, PIM1, RHOH, SOCS, and MYC, in 199 newly diagnosed grade 1 and 2 FLs. BCL2 mutations with VAF ≥20% occurred in 52% of cases. Among 97 FL patients who did not initially receive rituximab-containing therapy, nonsynonymous BCL2 mutations at VAF ≥20% were associated with increased transformation risk (HR 3.01, 95% CI 1.04-8.78, p = 0.043) and a trend toward shorter event-free survival (EFS, median 20 months with mutations versus 54 months without, p = 0.052). Other sequenced genes were less frequently mutated and did not increase the prognostic value of the panel. Across the entire population, nonsynonymous BCL2 mutations at VAF ≥20% were associated with decreased EFS (HR 1.55, 95% CI 1.02-2.35, p = 0.043 after correction for FLIPI and treatment) and decreased overall survival after median 14-year follow-up (HR 1.82, 95% CI 1.05-3.17, p = 0.034). Thus, high VAF nonsynonymous BCL2 mutations remain prognostic even in the chemoimmunotherapy era.
Details
- Title: Subtitle
- Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era
- Creators
- Cristina Correia - Division of Oncology Research, Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USAMatthew J Maurer - Department of Quantitative Health Sciences, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USASamantha J McDonough - Medical Genome Facility, Mayo Clinic, 200 First Street, S.W., Rochester, MN, 55905, USAPaula A Schneider - Division of Oncology Research, Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USAPaige E Ross - Genomics Systems Unit, Mayo Clinic, Rochester, MN, 55905, USAAnne J Novak - Mayo ClinicAndrew L Feldman - Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USAJames R Cerhan - Mayo ClinicSusan L Slager - Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USAThomas E Witzig - Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USABruce W Eckloff - Medical Genome Facility, Mayo Clinic, 200 First Street, S.W., Rochester, MN, 55905, USAHu Li - Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USAGrzegorz S Nowakowski - Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Nowakowski.Grzegorz@mayo.eduScott H Kaufmann - Mayo Clinic
- Resource Type
- Journal article
- Publication Details
- Blood cancer journal (New York), Vol.13(1), pp.81-81
- DOI
- 10.1038/s41408-023-00847-1
- PMID
- 37193683
- PMCID
- PMC10188323
- NLM abbreviation
- Blood Cancer J
- eISSN
- 2044-5385
- Grant note
- U01 CA195568 / NCI NIH HHS P50 CA097274 / NCI NIH HHS
- Language
- English
- Date published
- 05/17/2023
- Academic Unit
- Epidemiology
- Record Identifier
- 9984410789202771
Metrics
18 Record Views